Send to:

Choose Destination
See comment in PubMed Commons below
Acta Haematol. 2006;116(1):1-7.

The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.

Author information

  • 1Cleveland Clinic Foundation, Multiple Myeloma Multidisciplinary Clinical Research Program, Taussig Cancer Center, Cleveland, Ohio 44195, USA.


Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies. Substantial advances have been achieved in the past decade with the identification of cellular mechanisms that confer drug resistance. This has resulted in newer agents such as arsenic trioxide (Trisenoxt), lenalidomide (Revlimid) and bortezomib (Velcade) with promising activity in this disease. In this review article we will outline the history, mechanisms of action, pharmacology, and clinical trials of arsenic trioxide in multiple myeloma.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk